View Article

Abstract

Background: Fixed drug eruption (FDE) is a common adverse cutaneous reaction to drugs, but it is a complex and unusual diagnostic and clinical scenario that is not often encountered, particularly in the same patient for whom nephrolithiasis, stasis eczema and history of urinary tract intervention occur. Case Summary: A 48-year-old male chronic alcoholic, chronic smoker for 15 years, with bilateral renal calculi managed by RIRS + DJ stenting (in October 2025) and DJS exchange under anaesthesia in October 2025, presented in OPD of dermatology department at Government Medical College Hospital, The Nilgiris with one month history of well-defined bullous lesions present over bilateral palms on hyperpigmented skin with one hyperpigmented plaque over right leg (4x5 cm), one oral erosion (1x1 cm) over lower lip. The diagnosis was confirmed by dermatological evaluation (Fixed Drug Eruption due to Aceclofenac, differential diagnosis: Stasis Eczema). Urology work up (USG abdomen) showed tiny left renal calculi, fatty liver (Grade I), and a 2.4x2.3 cm cortical cyst in the upper pole of the left kidney and urine analysis was positive for sub clinical UTI with mild pus cells (6-8/HPF) and occasional bacteria. Conclusion: This case points out the need for being vigilant in FDE after urological procedures in patients using NSAIDs, the overlapping presentations of dermatological conditions, and the need for a multi-disciplinary approach. The use of the underreported FDE inducing agent aceclofenac is discussed in the context of the continuing urological disease.

Keywords

Fixed drug eruption, aceclofenac, renal calculi, stasis eczema, NSAID, bullous FDE, urolithiasis, multisystem drug reaction

Introduction

× Popup Image

Fixed drug eruption (FDE) is a unique type of cutaneous adverse drug reaction with the development of recurrence of lesions in the same body locations after re-exposure to the drug. Classically, FDE manifests as sharply delineated, round to oval erythematous or violaceous plaques which leave behind post-inflammatory hyperpigmentation, as described by Bourns in 18891. Then the vesicles or bullae filled with fluid develop on top of the hyperpigmented macules, which further increase the diagnostic possibilities and should be distinguished from Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and pemphigoid2.

The non-steroidal anti-inflammatory drugs (NSAIDs), such as aceclofenac, are the most commonly reported drug classes involved in FDE worldwide3,4. Aceclofenac, a potent COX-2 preferring inhibitor is very commonly used in India for musculoskeletal pain and for post procedural analgaesis after urological procedures like DJ stenting and RIRS. Though widely used, aceclofenac induced FDE is not as reported as other NSAIDs like ibuprofen and diclofenac in literature5.

The presence of FDE in conjunction with stasis eczema, nephrolithiasis, renal cortical cyst and history of prior urological surgeries in a chronic alcoholic patient presents a very challenging clinical picture. There is no systematic literature about the interaction between impaired renal function, altered drug metabolism, chronic alcohol use and cutaneous hypersensitivity to drugs. This case report proposes to document this uncommon multisystem presentation, to understand the pharmacologic background of aceclofenac induced FDE and to suggest a diagnostic and therapeutic approach for cases in various clinical scenarios.

2. Case Presentation

2.1 Patient Demographics and History

Mr. Manikandan appeared at the Department of Dermatology, Venereology and Leprosy (DVL) at the Government Medical College Hospital, The Nilgiris on June 5-6, 2026 and was aged 48 years. He was referred from the Urology OPD of Sree Abirami Hospital, Coimbatore, under follow-up for bilateral urolithiasis after 10 months. He was a 10-months follow-up patient in Urology OPD, Sree Abirami Hospital, Coimbatore.

His urological past included: (1) Bilateral RIRS + DJS done on October 6, 2025, for Left UU Calculus; (2) Left DJS exchange under anaesthetic on October 27, 2025 (with documentation of pullout/reinsertion); and (3) 7-month follow-up. He came to urology with new onset left flank pain of 1 month duration, without any dysuria. Urology provided uroprotective agents and imaging was arranged.

Alcoholic for 15 years and a smoker for 15 years. Personal history included normal bowel and bladder habits, and normal appetite and sleeping pattern. No dyspnea nor chest sign history.

2.2 Dermatological Presentation

At the time of examination at the DVL department, the patient was conscious, oriented, and had a good hydration status without fever. Vital signs were: BP 130/80 mmHg, SpO2 94%, PR 68 bpm. Systemic: CNS S1S2+, RS BLAE+, P/A Soft BS+, CNS NFND.

Dermatological exam (D/E) showed:

  • Two distinct 3x2 cm to 3x3 cm well defined hypopigmented/hyperpigmented bullae bilaterally over both palms on a background of hyper pigmentated skin.
  • A single well-defined hyperpigmented plaque of size 4x5 cm over the right leg
  • Erosion of the oral cavity measures 1 x 1 cm and is located over the lower lip.
  • Genitalia and scalp: Normal (N)

 

Figure 1. Fixed drug eruption: Cutaneous reactions.

(A)Clearly visible tense bulla with hyperpigmentation around the bulla on the palm side of the hand. (B) Residual hyperpigmentation with central bullous changes seen on the palm, typical of the fixed drug eruption.

Table 1: Summary of Laboratory Investigations

Investigation

Result

Normal Range

Clinical Significance

Urine Colour

Pale Yellow

Pale Yellow

Normal

Urine Appearance

Slightly Turbid

Clear

Suggests infection/inflammation

pH

6.5 (Acidic)

5.0–7.5

Normal

Specific Gravity

1.010

1.005–1.020

Normal hydration

Albumin

Nil

Nil

No renal protein loss

Sugar

Nil

Nil

No glycosuria

Bile Salts/Pigments

Negative

Negative

No hepatobiliary disease

Ketone Bodies

Negative

Negative

Normal

Nitrite

Negative

Negative

UTI not ruled out by nitrite alone

Pus Cells

6–8/HPF ▲

0–5/HPF

ELEVATED — suggests subclinical UTI

RBCs

1–2/HPF

0–5/HPF

Normal

Epithelial Cells

2–4/HPF

0–5/HPF

Normal

Bacteria

Present (occasional)

Nil

Indicates subclinical bacteriuria

Above normal range. HPF = High Power Field. (Sree Abirami Hospital Laboratory Report, 29/05/2026)

2.4 Imaging: USG Abdomen (Abirami Ultra Sonography Centre, 29/05/2026)

Table 2: USG Abdomen Findings — Mr. Manikandan Rao (Age 48/Male, Date: 29/05/2026)

Organ

Findings

Impression

Liver

Normal sized, increased echoes, no focal lesions; portal vein and biliary radicles normal.

Grade I Fatty Liver ▲

Gallbladder

Usually distended, with no stones or sludge.

Normal

Pancreas

Normal size, shape, echopattern; duct is normal; no calculi.

Normal

Spleen

N: 11.3cm, normal size, shape, echopattern

Normal

Right Kidney

11.2x5.1cm, normal pelvicalyceal system, present corticomedullary differentiation, no calculi.

Normal

Left Kidney

The size is 12.5 x 5.8 cm, and the cavity surrounding the kidney is normal, with a few small stones in the lower pole and a small cyst in the upper pole that measures 2.4 x 2.3 cm.

Renal calculi, small (left) ▲; Cortical cyst ▲

Urinary Bladder

Dilated; normal outline; No thickening/calculus; bilateral jets seen; Post-void residual: Nil.

Normal

Prostate

In this case, it is normal size (Volume 16 cc) and echoes.

Normal

Para-aortic Area

No swelling of the lymph nodes or presence of fluid in the abdomen/pleural cavity.

Normal

▲ Abnormal findings. CT KUB is recommended for further evaluation of calculi.

3. Diagnosis

3.1 Primary Diagnosis

Fixed Drug Eruption (FDE) - Aceclofenac-Induced / Stasis eczema

3.2 Differential Diagnosis

  • Stasis Eczema (if bilateral lower limb involvement, alcoholism and venous insufficiency are given, then it is considered as Stasis Eczema).
  • Diagnosis of pemphigus vulgaris requires an evaluation of the Nikolsky sign.Pemphigus vulgaris, oral erosion, requires evaluation of the Nikolsky sign.
  • Bullous lesions + mucous membrane involvement (excluding by localization, duration, pattern): Stevens-Johnson Syndrome / TEN.
  • Erythema multiforme (no target lesions found)
  • Bullous pemphigoid (age group, bilateral palmar distribution; IgG anti-BP180 not tested).

Table 3: Diagnostic Criteria for FDE - Applied to This Case (Based on Mahboob & Haroon, 1998; Lee et al., 2017)

Diagnostic Criterion

Standard

Present (palms together, leg):

Discrete, round/oval lesion(s)

Required

Present

Post-inflammatory hyperpigmentation (PIH)

Characteristic

These are small (3x2 to 3x3 cm) and present.

Bullous/vesicular variant

Severe form

Present (1x1 cm erosion)

Oral mucosal involvement

Supports diagnosis

Aceclofenac used post-DJS

Use the word "use" to refer to the time of a drug's consumption.

Essential

Not re-challenged (ethical)

When re-exposed, recurrence at the same site.

Pathognomonic

Pending follow-up

At the age of 10, she began to improve after she stopped taking the drugs.

Expected

Absent — supports FDE

Non-systemic drug reaction without features (fever, LFT, organ failure)

FDE vs. SJS/TEN

Present (palms together, leg):

4. Management

4.1 Dermatology Treatment (Govt. Medical College Hospital, The Nilgiris)

Table 4: Prescribed Treatment Protocol

Drug

Dose/Route

Frequency

Indication

Inj. Dexamethasone

2 cc IV

OD

Acute FDE anti-inflammatory

Inj. Pantocid (Pantoprazole)

IV

OD

GI protection with steroids

Tab. Vitamin C

250 mg

0-0

Wound healing, antioxidant

Tab. Cetirizine (Cephalexin 500mg?)

500 mg

2-2-2

Antipruritic/antihistamine

Tab. TPN 4 mg (Trypsin-Papain-Bromelain)

4 mg

0.5-0-1

Enzymatic debridement, anti-oedema

Silver Sulphadiazine Cream

External

B/D

Bullae/wound antimicrobial

Saline Gauze Dressing

External

V-V-V

Wound management

Clotrimazole + Betamethasone Ointment

External O/E

0-0

Plaque/eczema management

Tab. Prednisolone (Prednisolone?)

C/A

V-V-V

Stepdown steroid therapy

Note: Aceclofenac was found to be the cause and was promptly withdrawn. Orders placed: Investigations: USG abdomen + pelvis, Arterial Doppler B/L legs (DVL, 5/6/26).

4.2 Urological Follow-Up

Given the USG findings (small left renal stones, cortical cyst, fatty liver Grade I), a CT KUB was recommended to further characterise the stones. Uroprotective agents were continued on. Urine culture was recommended as active UTI was ruled out due to mildly elevated pus cells. Counselling of dietary modification (low oxalate, increased fluid) was provided.

5. Discussion

5.1 Epidemiology and Pathophysiology of Aceclofenac-Induced FDE

NSAIDs are one of the major groups of drugs responsible for FDE, which make up about 6–16% of all reported cutaneous adverse drug reactions in India6 along with antimicrobials and anticonvulsants. Aceclofenac is a phenylacetic acid derivative with preferential COX-2 inhibition which is one of the most widely used NSAIDs in the Indian subcontinent especially post orthopaedic and urological surgery7.

Immunopathogenesis of FDE involves activation of CD8+ T-lymphocytes at the site of the lesion, which on subsequent re-exposure release mediators of cell-mediated immunity such as perforin and granzyme B, which are responsible for the apoptosis of keratinocytes and the subsequent separation of the epidermis and dermis to form bullae8,9. FDE differs from other drug reactions by the recurrence of the reaction at the same site resulting in “memory T cells” in the dermis and in the epidermis. Studies in recent years have suggested that drug specific MHC-I restricted immune activation and memory intraepidermal effector T cells (CD69+CD103+) are the mechanism10.

FDE has a well-established predilection for involvement of acral sites (palms, soles) for mucosal surfaces. Palmar involvement as in this case can be confusing or difficult to diagnose because of the similar appearance with eczema of palms and soles, pompholyx, and contact dermatitis11.

5.2 Chronological Timeline and Drug Causality Assessment

Table 5: Clinical and Treatment Timeline

Date

Event

Dermatological Correlation

October 2025

RIRS + bilateral DJ stenting, NSAIDs (including aceclofenac) are prescribed for post-op analgesia.

Initial sensitisation to aceclofenac probably.

October 27, 2025

Under anaesthetic DJS changes (pull out + reinsertion), and NSAIDs re-prescribed.

Second exposure - FDE elicitation will likely occur.

November 2025 onwards

Follow up at 7 months and continued NSAID use for pain associated with the flanks.

Accumulation of drug exposure; lesion formation.

May 2026

Recurrence of left flank pain; Onset of skin lesions (bullae, plaque, oral erosion) ~1 month.

The onset of lesions was around 1 month prior to presentation in FDE.

29/05/2026

Urology OPD- urine analysis and USG abdomen done at Sree Abirami hospital, Coimbatore.

Urological work-up; subclinical UTI and calculi diagnosed.

05-06/06/2026

DVL department, Govt. Medical College Hospital, The Nilgiris, diagnosed and started treatment for FDE.

Aceclofenac identified and stopped; treatment begun.

Causality assessment was done by using the Naranjo Adverse Drug Reaction Probability Scale. The patient's score was +6 due to the following reasons: prior literature regarding aceclofenac-FDE (+1); improvement upon rechallenge (+1); recurrence on continued use (+2); the presence of alternative explanations that were not related to his current disease (+1); objective documentation of drug reaction (+1)12.

5.3 The Significance of Co-existing Urological Disease

Physiologic nephrolithiasis is associated with renal cortical cyst, which adds to the clinically relevant pharmacokinetic consideration. NSAIDs such as aceclofenac are excreted to a large extent by the kidney. Drug hypersensitivity reactions may occur at lower threshold levels due to prolonged plasma levels which can result from impaired renal clearance (due to obstructive uropathy, e.g., from previous DJ stenting or remaining calculi) [13]. The USG shows the fatty liver as Grade I, which further indicates reduced hepatic Phase I metabolism of aceclofenac (CYP2C9) that may lead to increased formation of the reaction metabolites involved in the pathogenesis of FDE14.

Another metabolic risk factor of chronic alcoholism (defined here as 15 years' duration) is CYP2E1 induction and CYP2C9 activity suppression, drug protein binding (decreased albumin), impaired immune regulation, and hepatic steatosis. The “perfect storm” for drug hypersensitivity is the combination of alcohol-related hepatic changes, renal insufficiency, and chronic NSAID use15.

Also worth noting is that stasis eczema features as a differential diagnosis and may also be a co-morbidity. Chronic venous insufficiency (suggested by the DVL team and requires arterial Doppler B/L legs) can result in palmar/plantar eczematous changes, hyperpigmentation, which can mimic or mask FDE. Arterial Doppler was ordered to rule out peripheral arterial disease which may be affecting skin changes on lower extremities16.

5.4 Novelty and Contribution to Literature

Table 6: Comparison with Published Cases of NSAID-Induced FDE

Author/Year

Drug

Site(s)

Variant

Special Features

Outcome

Bhutani et al. 2018 [3]

Ibuprofen

Lips, genitalia

Non-bullous

No systemic disease

Resolution

Nair et al. 2020 [5]

Aceclofenac

Trunk, thigh

Bullous

No prior surgery

Resolution

Singh et al. 2021 [17]

Diclofenac

Palms, soles

Non-bullous

Chronic kidney disease

Partial resolution

Current Case, 2026

Aceclofenac

B/L palms, R leg, oral

Bullous + oral + eczema

Renal calculi, DJ stenting, fatty liver, alcoholism

Under treatment

The features of this case which make it different from previous reports are: (1) The temporality with DJ stenting and RIRS procedures where aceclofenac was the main post-operative analgesic, (2) Trifocal FDE (bilateral palms, lower limb, and oral mucosa), which is a rare distribution pattern, (3) Complex pharmacokinetic milieu with the presence of renal calculi, cortical cyst, and Grade I fatty liver, (4) Alcohol use as a modifying factor for drug metabolism and immune response, and (5) The co-existence of features that suggest stasis eczema as an overlapping dermatological condition, which adds to the diagnostic complexity.

6. Patient Perspective

The bilateral bullae caused the patient a great deal of distress and did not allow him to perform his daily routines and work. He did not know that it was the pain medications causing his skin rash as he had thought that the rash was due to an infection or an allergic reaction to some unknown environmental triggers. He explained that the reason for the appearance of the drug, and questioned him about what he would do if he had pain in the future in connection with the condition of his kidneys. Advised about alternative analgesics (paracetamol, tramadol and selective COX-2 inhibitors with caution) and provided with a Medic Alert Card to avoid using Aceclofenac.

7. Conclusions

A rare and clinically complex case of aceclofenac induced bullous fixed drug eruption in a patient with multifaceted urological history, chronic alcoholism and fatty liver Grade 1. The case highlights the following key points in the clinical management of paediatric patients:

  • The use of aceclofenac, a commonly used drug for post-urological surgery in India, should be taken as an important cause of FDE, especially in patients with impaired renal or hepatic clearance.
  • A more severe form is called Trifocal FDE (bilateral palms, leg and oral mucosa) which requires prompt recognition and differentiation from SJS/TEN and the autoimmune bullous diseases.
  • In patients with overlapping disease systems, a multidisciplinary approach is mandatory that integrates dermatology and urology.
  • Drug hypersensitivity reactions could be exacerbated by the chronic alcoholism or hepatic steatosis, which may affect the metabolism of aceclofenac; this pharmacogenomic aspect should be studied.
  • Patients with lower limb venous insufficiency may also have stasis eczema that could be confused for FDE, therefore Doppler examination of the lower limbs is necessary.
  • Urine culture should be done after stents on patients with high urinary pus cells and USG does not fully define renal calculi, for which CT KUB should be ordered.

8. Learning Points for Clinicians

Clinical Point

Practical Implication

Oral erosion and bullous palms on bilateral palms after NSAID use are clinical features of FDE.

 

Always take drug history in bullous skin disease.

Aceclofenac is one of the most frequently reported, but underreported, FDE inducing NSAID in India.

 

Consider aceclofenac in all suspected NSAID-FDE in Indian patients.

Drug ADRs are increased with impaired renal/hepatic function.

Avoid/Do not use NSAIDs in CKD/fatty liver.

Stasis eczema and FDE may occur together, Doppler legs recommended if changes in lower limbs occur.

Do vascular work up if the diagnosis FDE is made with changes in lower limbs.

Urine culture is indicated in post-stent patients who have pus cells.

Don't overlook mild pyuria post-urological procedure.

Cortical renal cysts need periodic USG follow up, CT KUB for calculi stratification.

Important to have a structured urological follow-up plan.

Disclosures

Conflicts of interest: None declared.

Patient consent: Written informed consent was obtained from the patient for publication of this case report and accompanying clinical photographs.

Ethics approval: This case report was conducted in accordance with the Declaration of Helsinki. Patient data has been de-identified where possible.

REFERENCES

  1. Stubb S, Hasan T, Saksela E. Fixed drug eruption — clinical features and long-term observations. Dermatologica. 1985;170(2):63–66.
  2. Özkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008;6(3):181–188.
  3. Bhutani T, De Lima T, Khang P, Nguyen T. Ibuprofen-induced bullous fixed drug eruption. J Drugs Dermatol. 2018;17(3):354–355.
  4. Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008;74(4):430.
  5. Nair PA, Jivani NB, Diwan NG. Fixed drug eruption due to aceclofenac: a case report. Int J Res Dermatol. 2020;6(3):432–434.
  6. Pudukadan D, Thappa DM. Adverse cutaneous drug reactions: clinical pattern and causative agents in a tertiary care center in South India. Indian J Dermatol Venereol Leprol. 2004;70(1):20–24.
  7.  Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004;5(6):1347–1357.
  8. Teraki Y, Shiohara T. IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol. 2003;112(3):609–615.
  9. Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol. 2007;17(3):201–208.
  10. Lee JY, Kim YC. Fixed drug eruption: updates on pathogenesis. Clin Exp Dermatol. 2017;42(8):835–843.
  11. Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30(11):1011–1030.
  12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
  13. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24S.
  14. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120(3):594–606.
  15. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.
  16. Mekkes JR, Loots MAM, Van Der Wal AC, Bos JD. Causes, investigation and treatment of leg ulceration. Br J Dermatol. 2003;148(3):388–401.
  17. Singh R, Chhabra S, Puri N. Diclofenac-induced fixed drug eruption with palmar involvement in a patient with chronic kidney disease: a case report. Indian Dermatol Online J. 2021;12(4):598–600

Reference

  1. Stubb S, Hasan T, Saksela E. Fixed drug eruption — clinical features and long-term observations. Dermatologica. 1985;170(2):63–66.
  2. Özkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008;6(3):181–188.
  3. Bhutani T, De Lima T, Khang P, Nguyen T. Ibuprofen-induced bullous fixed drug eruption. J Drugs Dermatol. 2018;17(3):354–355.
  4. Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008;74(4):430.
  5. Nair PA, Jivani NB, Diwan NG. Fixed drug eruption due to aceclofenac: a case report. Int J Res Dermatol. 2020;6(3):432–434.
  6. Pudukadan D, Thappa DM. Adverse cutaneous drug reactions: clinical pattern and causative agents in a tertiary care center in South India. Indian J Dermatol Venereol Leprol. 2004;70(1):20–24.
  7.  Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004;5(6):1347–1357.
  8. Teraki Y, Shiohara T. IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol. 2003;112(3):609–615.
  9. Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol. 2007;17(3):201–208.
  10. Lee JY, Kim YC. Fixed drug eruption: updates on pathogenesis. Clin Exp Dermatol. 2017;42(8):835–843.
  11. Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30(11):1011–1030.
  12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
  13. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24S.
  14. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120(3):594–606.
  15. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.
  16. Mekkes JR, Loots MAM, Van Der Wal AC, Bos JD. Causes, investigation and treatment of leg ulceration. Br J Dermatol. 2003;148(3):388–401.
  17. Singh R, Chhabra S, Puri N. Diclofenac-induced fixed drug eruption with palmar involvement in a patient with chronic kidney disease: a case report. Indian Dermatol Online J. 2021;12(4):598–600

Photo
Ranilboopathi S.
Corresponding author

Department of Pharmacy Practice, JSS College of Pharmacy, Ooty

Photo
Kanthimathi Meenal C. T.
Co-author

Department of Pharmacy Practice, JSS College of Pharmacy, Ooty

Photo
Naveen N. Prabhu
Co-author

Department of Pharmacy Practice, JSS College of Pharmacy, Ooty

Ranilboopathi S., Kanthimathi Meenal C. T., Naveen N. Prabhu, A Rare Multisystem Presentation of Fixed Drug Eruption Due To Aceclofenac in A Patient with Bilateral Renal Calculi and Stasis Eczema – A Case Study, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 6, 7345-7354. https://doi.org/10.5281/zenodo.21042397

More related articles
A Prospective Observational Study On Usage Pattern...
M. Nisar Ahamed, Venkat Ramesh, Issac Illuri, Bandhal Vinod Mouni...
Toxicity Outcomes of Cisplatin-Based Chemotherapy ...
Dr. Vishal Toka , Shaik Mushtak Hussain, Mogilicharla Archana , J...
Review On Recent Advances in Nitrogen Heterocycles: Synthesis, Properties, And E...
Kadeeja Jumailath V. H., Dr. G. Babu, Ayswarya K., Dr. Byju K., Anudhanya Parengal...
Formulation of Tablet using different Natural Binder and Evaluation of their eff...
Misba Mujawar, Ujma Belif, Ashwini Aldar, Dineshbabu Naidu...
Formulation and evaluation of herbal Anti arthritis oil using Zingiber Officinal...
Khushbu Mohourle, Nutan Bodhale, Vaishnavi Rajurkar, Vaishnavi Shankarpure, Irshad Ahmad ...
More related articles
A Prospective Observational Study On Usage Patterns Of Teicoplanin In Different ...
M. Nisar Ahamed, Venkat Ramesh, Issac Illuri, Bandhal Vinod Mounika, Nikitha Chidurala, Prasanna Val...
Toxicity Outcomes of Cisplatin-Based Chemotherapy in Cervical and Head & Neck Ca...
Dr. Vishal Toka , Shaik Mushtak Hussain, Mogilicharla Archana , Jarupla Mahika ...
A Prospective Observational Study On Usage Patterns Of Teicoplanin In Different ...
M. Nisar Ahamed, Venkat Ramesh, Issac Illuri, Bandhal Vinod Mounika, Nikitha Chidurala, Prasanna Val...
Toxicity Outcomes of Cisplatin-Based Chemotherapy in Cervical and Head & Neck Ca...
Dr. Vishal Toka , Shaik Mushtak Hussain, Mogilicharla Archana , Jarupla Mahika ...